MFluidx

MFluidx specializes in innovative point-of-care molecular diagnostics, providing rapid and accurate testing solutions that rival traditional PCR tests while maintaining cost-effectiveness. MFluidx focuses on developing advanced diagnostic technologies, with its headquarters located in Berkeley, US. Founded in 2016 by Charlie Yeh, the company has participated in 2 funding rounds, the latest being in January 2019, where they raised an undisclosed amount from Blue Bear Ventures. MFluidx is focused on developing a point-of-care molecular diagnostic test known as the "SIMPLE CHIP," which operates at a cost comparable to rapid antigen tests while providing results equivalent to those obtained through PCR testing.

This technology employs microfluidics to create a low-cost consumable cartridge and reader instrument capable of detecting multiple infectious agents from a single patient sample. The SIMPLE CHIP is tailored for environments such as small clinics and pharmacies, enabling rapid, decentralized screening within 7 to 15 minutes. MFluidx caters to various clients, including healthcare providers and diagnostic laboratories, primarily in the United States and potentially in international markets requiring rapid diagnostic testing. MFluidx's revenue model is based on direct sales of its SIMPLE CHIP product, along with partnerships with healthcare providers and diagnostic laboratories.

The company engages in transactions involving the sale of consumable cartridges and reader instruments essential for their diagnostic technology. Their business model supports both B2B and direct-to-consumer sales, thus providing clinics and pharmacies access to the SIMPLE CHIP for quick diagnostics while ensuring pricing is accessible and maintains profitability. MFluidx intends to expand its product offerings, with upcoming launches of new diagnostic tools designed for broader application in healthcare settings. The company is actively pursuing opportunities to enter international markets, targeting regions where rapid diagnostic testing is in demand by 2023.

The funding raised in January 2019 will support these strategic initiatives, enhancing their research and development capabilities to innovate and improve their product line.